The glycopeptide antibiotics, including vancomycin and teicoplanin, are thought to act by specifically binding the terminal D-alanyl-D-alanine of the disaccharide-pentapeptide precursor as it appears at the surface of the cytoplasmic membrane (9) . A propensity for dimerization leads to cooperative binding of the target, which increases the activity of the antibiotic (3, 13) . An exception to this is teicoplanin, which apparently relies on an acyl membrane anchor to provide binding stability (3) . High-level acquired resistance to glycopeptides (teicoplanin and vancomycin) has recently appeared in species of the genus Enterococcus, particularly in Enterococcus faecalis and Enterococcus faecium (2) . The mechanism has been well delineated and is due to the synthesis of a novel cytoplasmic peptidoglycan precursor (4), UDP-muramyl-tetrapeptide-Dlactate, which has a markedly decreased affinity for the glycopeptide antibiotics vancomycin and teicoplanin (5) . One of the worrisome possibilities is that this resistance, encoded within a transposon (2) , frequently on plasmids, could undergo intergeneric transfer to a more virulent organism, such as Staphylococcus aureus. In fact, such transfer has been shown to occur in the laboratory (17) .
For staphylococci, another pathway to resistance apparently exists via mutation (12, 18, (21) (22) (23) (24) . In contrast to the enterococci, staphylococci are generally more susceptible to vancomycin than to teicoplanin (12, 18, 23) , the resistant isolates that have been tested and reported thus far are always more resistant to teicoplanin than to vancomycin (12, 15, 18, (21) (22) (23) (24) , and resistant derivatives are more readily selected with teicoplanin (12, 23) . Staphylococcus haemolyticus strains resistant to teicoplanin were recognized before the release of the antibiotic to the market (18) . The emergence of S. haemolyticus strains that are resistant to vancomycin during therapy in humans has also been reported (21) .
The resistant strains of staphylococci express increased levels of a membrane protein variously described as either 35 or 39 kDa (6, 18, 24) . Milewski et al. (16) have recently characterized this protein in S. aureus as a member of the family of dehydrogenases which includes the D-hydroxy acid dehydrogenase (VanH) associated with vancomycin resistance in enterococci (2) . These data suggest that the mechanism of resistance in staphylococci may resemble that in enterococci. The vanZ gene of the vancomycin-resistant enterococci, by an as-yetunknown mechanism, appears to code for a phenotype of teicoplanin resistance when it is expressed on a high-copynumber plasmid. This phenotype is reminiscent of glycopeptide resistance in staphylococci (1) .
We herein describe the structures of cytoplasmic peptidoglycan precursor and of a significant portion of mature peptidoglycan of an isogenic series of S. haemolyticus strains expressing increasing levels of resistance to the glycopeptide antibiotics teicoplanin and vancomycin. Although the general structure of the peptidoglycan of some coagulase-negative species of staphylococci has been previously described (20) , that of S. haemolyticus has not, to our knowledge, been examined prior to this work.
MATERIALS AND METHODS
Strains and growth conditions. All strains used in this study are listed in Table  1 . S. haemolyticus 18 (11) has been described previously. Strains 18-73 and 18-88 are consecutive one-step mutants of strain 18 with increasing levels of resistance to vancomycin. They were routinely cultured on brain heart infusion medium (Difco, Detroit, Mich.) at 37ЊC with agitation. The MICs of vancomycin and teicoplanin were determined by diluting the antibiotics twofold serially through brain heart infusion agar. Strains were spotted on the agar plates with a Steers replicator so that each spot contained 10 4 CFU. Preparation of peptidoglycan precursors. Peptidoglycan precursors were extracted and purified as previously described (4) . In order to accumulate cytoplasmic precursors, cells were exposed for the last 30 to 60 min of growth to ramoplanin (either 0.5 or 1 g/ml; Marion Merrell Dow, Lepetit Research Center, Geranzano, Italy), which prevents the formation of lipid intermediate II from I (25), or to vancomycin (1 mg/ml; Lilly, Paris, France). Digestion of the entire cytoplasmic extract with R39 D,D-carboxypeptidase was performed as previously described (4) .
Preparation of peptidoglycan. Peptidoglycan was extracted essentially as described by de Jonge et al. (7) . One difference was that the final pellet of purified peptidoglycan, usually between 15 and 30 mg, was digested in its entirety for 16 h at 37ЊC in 25 mM phosphate buffer (pH 6.5) containing 10 mM MgCl 2 with egg-white lysozyme (200 g/ml) and M-1 muramidase (250 g/ml) (Sigma Chemical Corp., St. Louis, Mo.). The enzymes were then inactivated by boiling for 3 min in water. After centrifugation the supernatants were stored at Ϫ20ЊC. We estimate that 85 to 95% of staphylococcal peptidoglycan was digested by this treatment (8) .
Separation of muropeptides. Before separation the sample was mixed with an equal volume of 0.5 M borate buffer (pH 9) and reduced with sodium borohydride for 15 min at room temperature. The pH of this solution was adjusted to 2 with orthophosphoric acid. Samples were kept at Ϫ20ЊC. The high-performance liquid chromatography (HPLC) system consisted of an L6200 A pump and an L4250 UV detector (Merck), a 717 autosampler (Waters Corporation, Milford, Mass.), and a D2500 Chromatointegrator (Merck).
Samples were applied to a 3-m Hypersil C 18 reversed-phase column (250 by 4.6 mm; Interchim) guarded by a Lichrospher 100 RP18 (5 m; Merck) precolumn. The column was eluted at a flow rate of 0.5 ml/min with a linear gradient of 0.05% trifluoroacetic acid (TFA) in water to 20% CH 3 CN with 0.035% TFA in 90 min, starting 10 min after injection of the sample. The elution was continued for 20 min with 0.035% TFA in 20% CH 3 CN. The column temperature was maintained at 30ЊC, and the eluted compounds were detected by A 210 .
Identification of the peaks. Liquid chromatography-mass spectrometry (LC-MS) was performed with a Hewlett-Packard HP1090 Series II liquid chromatograph coupled to either a Finnigan (San Jose, Calif.) TSQ700 triple-quadrupole mass spectrometer or a Sciex (Thornhill, Ontario, Canada) API-III triple-quadrupole mass spectrometer, both equipped with nebulizer-assisted electrospray sources. Data acquisition was performed between 500 and 1,900 Da with scan times on the order of 2 to 3 s. The fact that molecules of higher mass were multiply charged allowed identification of these structures. No eluent splitting was used with the Finnigan instrument, whereas the eluent flow entering the Sciex was split 10:1 so that about 20 l/min was entering the mass spectrometer. MS-MS was performed on singly and doubly charged protonated molecules with either helium or argon as the collision gas. To determine the relative contribution of each mass species to a given peak, when appropriate, the mass spectra were deconvoluted to convert all multiply charged ions into singly charged species. The resulting peak heights were then considered to be proportional to the abundance of each component.
Confirmations of the muropeptide structures deduced from the mass spectrometry were accomplished with different samples either by fragmentation with an MS-MS system or chemically after purification of the peak by HPLC with the gradient described above during a 60-min run and a 5-m Lichrospher 100 RP18 column (125 by 4 mm; Merck). The N-acetyl-muramicitol concentration and amino acid composition of the muropeptides were determined after hydrolysis by 6 N HCl at 95ЊC for 16 h by the Waters AccQ Tag method. The different components were separated by HPLC and detected with a Waters 474 scanning fluorescence detector and a column (150 by 3.9 mm) supplied with the Waters kit; the gradient recommended by the manufacturer was used. The sequence of amino acids within cross bridges was determined by Edman degradation with material from purified muropeptides as described above.
Competition of soluble glycopeptide target for vancomycin. Staphylococcal strains were grown on agar plates at 37ЊC overnight. Cells were collected with an inoculating loop and suspended in Mueller-Hinton broth (Difco) adjusted to pH 6.8 with 1 N HCl to an optical density at 260 nm of 0.5. The suspension was diluted 1,500-fold, and 60 ml of the mixture was layered on 75-ml MuellerHinton (pH 6.8) agar plates and allowed to settle several minutes before the excess broth was removed. The plates were allowed to dry. A fixed concentration of vancomycin (20 g/25 l of reaction mixture) was incubated briefly with increasing concentrations of L-Ala-␥-D-iso-glutamyl-L-Lys-D-Ala-D-Ala (Sigma Chemical Corp.) before the entire mixture was loaded on sterile 7-mm-diameter paper disks that had been placed on the seeded agar plates. The plates were incubated at 37ЊC overnight, and the zone sizes were measured. A standard curve of increasing concentrations of vancomycin was similarly prepared and read as a control.
RESULTS
Cytoplasmic precursors of peptidoglycan biosynthesis. Soluble UDP-containing precursors were extracted from strains 18 and 18-88 as previously described (4) . The extractions were performed with accumulation of cytoplasmic precursors in the presence of ramoplanin. The results are shown in Fig. 1 . Peak 1 represents UDP-muramyl-pentapeptide, with a monoisotopic mass of 1,149 Da as confirmed by amino acid analysis. Peak 2 contains UDP-muramyl-tetrapeptide-D-lactate, with a monoisotopic mass of 1,150 Da. Aside from its mass, the material in peak 2 runs in the same position as control UDPmuramyl-tetrapeptide-D-lactate purified from vancomycin-resistant enterococci. No mass could be detected in this area for precursors extracted from strain 18, as shown in Fig. 1 . To further characterize the material in peak 2 of strain 18-88, the extracts of strains 18 and 18-88 were subjected to digestion by purified R39 D,D-carboxypeptidase (4) . This enzyme cleaves the terminal D-alanine or D-lactate. The digested extracts were subjected to LC-MS (data not shown); in both cases, the material in the pentapeptide peak had disappeared while a new peak, with a retention time of 13 min, appeared with a monoisotopic mass of 1,078 Da, consistent with a tetrapeptide. The R39 carboxypeptidase-treated extract from strain 18-88 showed no detectable peak at 27 min, suggesting that the material in the undigested sample running with this retention time and having a mass of 1,150 Da was also converted to UDP-muramyl-tetrapeptide and therefore was UDP-muramyltetrapeptide-D-lactate. Integration of the areas of the various peaks (data not shown) reveals that peak 2 accounted for 1.7% of total identifiable UDP-muramyl precursors in strain 18-88 and less than 0.2% in strain 18.
Peptidoglycan structure of S. haemolyticus strains with increasing resistance to glycopeptides. The separations by HPLC of muropeptides derived from the peptidoglycan of the susceptible S. haemolyticus strain 18 and its resistant derivatives, 18-73 and 18-88, are shown in Fig. 2 . Each peak for which we were able to determine at least one molecular mass was as- Table 2 . As can be seen, the peptidoglycan of these strains, like that of other staphylococci, appears to be highly cross-linked (89% of peptidoglycan in dimers or higher-order polymers) ( Fig. 2 and Table 2 ). Two pieces of evidence confirm that the material in peak 16 and beyond contains primarily muropeptides: amino acid analysis of this material confirms that there is little contamination, and our mass data on these peaks are consistent with the possibility that peak 16 contains pentameric muropeptides and other peaks, in some cases, contain higher-order polymeric muropeptides.
In the case of S. haemolyticus, multiple peaks (e.g., peaks 4, 11, 13, 14, and 15) contain two or more muropeptides as determined by mass spectrometry. When this was the case, the proposed muropeptide structures were given subdesignations (e.g., 4a, 4b, etc.), which are shown in Fig. 3 . Amino acid analysis was performed for muropeptides 2, 6, and 7 as indicated in Table 2 , and in each case the proposed structure was confirmed. The proposed sequence of amino acids in the cross bridge was based on N-terminal amino acid sequencing of purified material derived from peaks 6 and 7.
Muropeptides 1 to 4 could be the result of peptidoglycan breakdown. The structure contained in peak 1, with a mass of 498 Da, is presumed to represent the disaccharide GlcNAcMurNAc and could be the result of an amidase activity. Muropeptide 2, which was purified and subjected to amino acid analysis (Table 2) , contains no N-acetylglucosamine and could result from the activity of a glucosaminidase. Muropeptide 3 could result from endopeptidase activity similar to that of lysostaphin (19) and a carboxypeptidase. Muropeptide 4 could result from endopeptidase activity.
Structures 6 and 7 are monomeric disaccharide-pentapeptides with their cross bridges attached. Their structures were confirmed by analysis of amino acid content, and the positions of the alanine and serine in the cross bridge were assigned on the basis of amino acid sequence data from analysis by Edman degradation. The deduced structures are generally similar to those published previously for Staphylococcus epidermidis and Staphylococcus saprophyticus (20) .
Peaks 8, 9, 11, and 13 contain dimeric muropeptides for which the pentapeptide monomer has served as the acceptor molecule. Peaks 10 and 12 appear to contain dimeric muropeptides of the tripeptide-tripeptide variety. Peaks 14 and 15 contain trimeric muropeptides, again including a pentapeptide as an acceptor. Peak 16 (structure not shown) is a pentameric muropeptide. Mass data obtained from some later peaks (not shown) indicate that these too contain muropeptides. A comparison of the proposed cross bridges in the resistant strains, 18-73 and 18-88, and the susceptible parent, strain 18, was carried out on the basis of the observed masses in some peaks. Peaks 11, 13, 14, and 15 contain several comigrating muropeptides. Peak 11 for strain 18 contains structures with masses of 2,477 (11a), 2,457 (11b), and 2,507 (11c) Da (Fig.  3A) , whereas peak 11 for strains 18-73 and 18-88 ( Fig. 3B and  C) contains, besides structures 11a and 11c, structures 11d and 11e, with monoisotopic masses of 2,249 and 2,537 Da, respectively (Fig. 4) . Analysis of the deconvoluted mass spectrum of the material in peak 11 showed that for strain 18, muropeptides 11a, 11b, and 11c contribute 29, 46, and 25%, respectively, to the total, whereas for strain 18-73, muropeptides 11a, 11c, 11d, and 11e (no muropeptide 11b could be detected) contributed 19, 36, 25, and 20%, respectively, to the total peak material. Strains 18-73 and 18-88 have the muropeptide shown in peak 13d (Fig. 3B ) in addition to those for 13a to 13c (Fig.  3A) . The relative contributions of muropeptides 13a, 13b, and 13c to peak 13 in strain 18 are 39, 36, and 25%, respectively, while for strain 18-73, the relative contributions of muropeptides 13a, 13b, 13c, and 13d are 0 (undetectable), 22, 52, and 25%, respectively. Therefore, a muropeptide containing a cross-link with Ser 2 appeared in peaks 11 and 13 in strains 18-73 and 18-88 in the place of GlySer in strain 18 (Fig. 3) . Quantitatively, this involved approximately 20% of the material in peak 11 and 25% of the material in peak 13. The position of the second serine was deduced on the basis of an analysis of precursors in S. haemolyticus strains in which a precursor bearing a GlySer partial cross bridge was detected (data not shown). Peaks 14 and 15, like peaks 11 and 13, each contained multiple comigrating muropeptides with different cross bridges. In this case the proposed structures are summarized in Table 3 . Also shown in Table 3 is the contribution of each of the various mass signals to the total material in the peak. It appears that the predominant cross bridge in the muropeptide of peak 14 from strain 18 contains Gly 2 SerGly 2 , whereas strains 18-73 and 18-88 have a greater number of cross bridges containing GlySer 2 Gly 2 . The same phenomenon can be seen for the muropeptides in peak 15: strain 18 has cross bridges containing Gly 2 SerGly 2 , AlaGly 4 , or AlaGlySerGly 2 , whereas strains 18-73 and 18-88 have more cross bridges containing GlySer 2 Gly 2 and AlaGlySer 2 Gly (although, in this case, the position of the second serine has not been established). In peak 14 of peptidoglycan from strain 18, no muropeptides contain Ser 2 ; in peak 14 from strain 18-73, 100% of the trimeric muropeptides contain at least one cross bridge with Ser 2 . The situation is similar for peak 15, where only 32% of the muropeptides from strain 18 contain one cross bridge with Ser 2 , while 100% of the trimeric muropeptides in peak 15 from strain 18-73 contain Ser 2 in at least one cross bridge. From the data presented in Table 2 and from our estimate of the contributions of each component from the deconvoluted mass spectra of peaks 11, 13, 14, and 15, we estimate that cross bridges containing Ser 2 have replaced GlySer in 10.5 to 13.6% of peptidoglycan in strain 18-73 as opposed to strain 18. Strain 18-88 is very similar to strain 18-73 except that there appear to be more lower-molecular-weight structures, as indicated by peaks E, F, G, and H (Fig. 3C) . The position of these putative low-molecular-weight muropeptides, with the exception of muropeptide F, seems inappropriately late in the chromatogram, but the proposed structures account for the observed masses. These putative structures would, again, probably result from limited peptidoglycan breakdown. Muropeptides 3 to 5 are present in peptidoglycan of all strains.
Competition of soluble glycopeptide target for vancomycin. Soluble pentapeptide competes more effectively for vancomycin in the presence of strain 18-88 than in the presence of strain 18 (Fig. 5) . This difference cannot be accounted for by the difference in vancomycin susceptibility of the two strains as demonstrated by our standard bioassay curves (data not shown). Identical experiments with teicoplanin (data not a For strain 18-73, muropeptides 3, B, and C were contained within peak 3. For strain 18-88, muropeptides 3 and F were contained within peak 3, and muropeptides 4 and H were contained within peak 4. ND, not detected.
b Muramicitol, N-acetyl-muramicitol. c Shown only for peaks subjected to amino acid analysis. The amino acid content and N-acetyl-muramicitol content are molar concentrations per mole of material in the peak. Glu, glutamic acid.
shown) revealed no difference between the two strains in competition of soluble pentapeptide target for the antibiotic. (16) suggested that an altered UDP precursor might also exist in resistant strains of staphylococci. Our data, unlike those of others (27) , are consistent with their observations. Other workers have probably not detected this small amount of D-lactatebearing precursor because the HPLC analysis alone is not sufficiently sensitive. Only with the aid of LC-MS were we able to detect this structure. However, it is not clear that 1.7% of total precursor as depsipeptide can explain the resistance of this strain. In one study of enterococcal strains (10), 10% of total precursor as depsipeptide increased the MIC of vancomycin from 2 to 32 g/ml. In the case of S. haemolyticus, the MIC of vancomycin increases from 4 to 16 g/ml with only 1.7% of precursor as depsipeptide.
Staphylococcal peptidoglycan is composed, as previously suggested by Schleifer and Kandler (20) and de Jonge et al. (7), of a lysine muropeptide acceptor containing at its ε-amino position a substitution of a glycine-containing cross bridge to the D-alanine 4 of the donor. We were unable to identify disaccharide-tetrapeptide-D-lactate as monomer or acceptor. This is not surprising, given the small amount of D-lactatebearing precursor present and the somewhat limited sensitivity of the peptidoglycan analysis. S. haemolyticus 18 and 18-73 contain, within their peptidoglycan, structures which appear to represent simply the dissaccharide (peaks with masses of 498 Da) which could result from an amidase-like activity. The peptidoglycan of S. haemolyticus 18 and 18-73 also contains structures which could be branched muramyl tetrapeptides (peak 2), which would result from a glucosaminidase activity. A glucosaminidase activity has been described for S. aureus (26) .
In the case of S. haemolyticus, even the most susceptible strain of our series, strain 18, synthesizes several different cross bridges, the most common being Gly 2 SerGly 2 or, less frequently, AlaGlySerGly 2 . S. haemolyticus, like fem mutants of S. aureus (14) , is less susceptible than S. aureus to digestion by lysostaphin (19, 22) ; this is probably explained by the presence of alanine and serine in place of glycine within the cross bridges of the peptidoglycan of these strains. Strains 18-73 and 18-88 have more cross bridges containing GlySer 2 Gly 2 and AlaGlySer 2 Gly. Although we have been able to analyze only up to half of the muropeptides of the peptidoglycan of these strains, our data might indicate that as much as 13.6% or more Muropeptides B and C were found within the same peak. (C) Structures proposed for muropeptide fragments unique to strain 18-88 compared with strains 18 and 18-73. Muropeptides F and G were found within the same peak. In other instances in which more than one molecule has been identified within one peak, the structure has been given a lettered subdesignation (e.g., structures 4a and 4b). Subdesignations unique to one strain are shown as such. Cross bridges for peaks 14 and 15, designated as 1, 2, and 3, are described in Table 3 (Tables 2 and 3 ). Since strain 18-73 does not demonstrate altered expression of penicillin-binding proteins (22) , the presence of additional serines in the cross bridge cannot be related simply to altered penicillin-binding protein expression.
At the same time, we examined the contribution of cooperative glycopeptide binding to antibiotic activity in these strains. These experiments were based on those recently described by Beauregard et al. (3) . We observed that the soluble pentapeptide target was more effective at competing for the binding of vancomycin in the presence of the resistant strain than in the presence of the susceptible strain. Experiments with teicoplanin demonstrated no difference in target competition for the two strains. Vancomycin is thought to act partly via dimerization and cooperative binding, while teicoplanin is thought not to dimerize but rather to rely on a membrane anchor for stable binding. Our data suggest that resistance is directed, in part, towards the binding of vancomycin dimers to target (and, therefore, cooperative binding) in situ. Whether the altered peptidoglycan cross bridge can explain this by interference with vancomycin dimerization and binding in situ is as yet unknown. Since teicoplanin does not bind its target in a cooperative manner, these experiments cannot address resistance to this glycopeptide in these strains. In conclusion, it is possible that glycopeptide resistance in S. haemolyticus is multifactorial in nature and that both the presence of UDP-muramyl-tetrapeptide-D-lactate cytoplasmic precursor and altered peptidoglycan cross bridges contribute to this resistance.
